Astellas Pharma’s Padcev Receives NMPA Approval for Urothelial Cancer Treatment
TOKYO—Astellas Pharma Inc. (TYO: 4503) has announced that its anti-HER3 antibody-drug conjugate (ADC), Padcev (enfortumab...
BioNTech’s BNT326/YL202 Clears FDA Hurdle, Advancing in Clinical Trials for Solid Tumor Treatment
FRANKFURT—BioNTech SE (NASDAQ: BNTX), a leading German biotechnology company, has announced that the US Food...
Jiangsu Hengrui Pharmaceuticals Expands R&D Footprint with Jinan Innovation Zone Partnership
JINAN—The management committee of the Jinan Innovation Zone has entered into a strategic partnership with...
China’s NMPA Grants Medical Device License to DaAn Gene’s Monkeypox Detection Kit
GUANGZHOU—DaAn Gene Co., Ltd, a subsidiary of Sun Yat-sen University based in China (SHE: 002030),...
Genesis MedTech’s J-VALVE System Transfers to Edwards Lifesciences, Marking a New Era in Aortic Valve Treatment
SINGAPORE—In a strategic move to strengthen its position in the global medical device market, Edwards...
Changchun High & New Technology Secures NMPA Approval for Turner Syndrome Treatment
CHANGCHUN—Changchun High & New Technology Industries (Group) Inc., (SHE: 000661), a leading biopharmaceutical company in...
AstraZeneca’s Fasenra Secures NMPA Approval for Severe Eosinophilic Asthma Maintenance Therapy
BEIJING—The National Medical Products Administration (NMPA) of China has granted market approval for AstraZeneca (NASDAQ:...
Genmab’s Tepkinly/Epkinly Receives EC Nod for Relapsed Lymphoma Treatments
COPENHAGEN—Genmab A/S (NASDAQ: GMAB), a leading biotech company, has announced that the European Commission (EC)...
Multitude Therapeutics and Adcendo ApS Partner on Anti-TF ADC, Targeting Global Cancer Treatment
SHANGHAI/COPENHAGEN—In a strategic move to bolster cancer treatment options, Shanghai-based medical technology company Multitude Therapeutics...
Lepu Medical Secures Approval for RECATCHOR Catheter, Enhancing Cardiovascular Procedures
Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...
Beijing Proposes New Regulations to Enhance Pharmaceutical Retail Standards and Services
The Beijing Municipal Medical Products Administration has unveiled a draft proposal titled “Guiding Opinions on...
AstraZeneca’s Imfinzi Gains FDA Approval for Neoadjuvant Use in Early-Stage Lung Cancer
AstraZeneca (NASDAQ: AZN, LON: AZN) , the UK-based pharmaceutical powerhouse, has secured US FDA approval...
RemeGen Reports 75.6% Revenue Surge in H1 2024, Driven by Key Product Sales
RemeGen (HKG: 9995) has reported a robust performance in its first half of 2024, achieving...
Robotrak Secures NMPA License for China’s First Smart Ophthalmic Navigation Laser
Robotrak, a Nanjing-based ophthalmic innovation platform, has secured a Category III medical device license from...
Sichuan Biokin Launches Phase III Trial for Bispecific ADC BL-B01D1 in Lung Cancer
Sichuan Biokin Pharmaceutical Co., Ltd. (SHA: 688506) has commenced the first patient dosing in a...
Yixintang Partners with Huawei Cloud to Drive Digital Transformation in Pharma Retail
Yixintang Pharmaceutical Group Co., Ltd. (SHE: 002727), a prominent pharmaceutical retail chain in China, has...
Ant Group Eyes Acquisition of Leading Internet Healthcare Platform Haodf.com
Ant Group, the China-based fintech powerhouse, is reportedly pursuing the acquisition of Haodf.com, one of...
CARsgen Completes Patient Enrollment for Phase II Trial of CT041 in Advanced Gastric Cancer
CARsgen Therapeutics Holdings Ltd (HKG: 2171), a leading China-based developer of chimeric antigen receptor (CAR)-T...
Bio-Thera Solutions Expands Reach with New Licensing Deal for Biosimilar BAT2306
Guangzhou-based Bio-Thera Solutions (SHA: 688177) has entered into a new licensing agreement with Russian firm...
Evotec to Cut 400 Jobs Amid R&D Slowdown and Corporate Restructuring
Evotec SE (NASDAQ: EVO), a Germany-based Contract Research and Development Organization (CRO/CDMO), has announced plans...